Journal of International Psychiatry

[Abstract] Objective: To explore the value of paroxetine in the treatment of type 2 diabetes patients with depression, and analyze the efficacy of the program and its impact on mental status. Methods: The researchers randomly selected 98 patients with type 2 diabetes and depression diagnosed by doctors in our hospital through relevant examinations from October 2020 to October 2022. After admission, 49 patients in each group were divided into odd and even numbers. The patients in the control group were treated with conventional symptomatic support treatment, and the patients in the observation group were treated with paroxetine on the basis of the control group. The clinical efficacy after treatment was statistically analyzed, and the psychological status and metabolic indicators of anxiety and depression in patients before and after treatment were evaluated. Results: After treatment with paroxetine, the recorded clinical efficacy of 49 patients in the observation group was 95.92%, which was higher than that in the control group (P<0.05); The results of anxiety and depression recorded in the observation group at 2, 4, and 8 weeks after treatment were significantly lower than those in the control group (P<0.05); The PHQ9 score recorded in the observation group was significantly lower than that in the control group (P<0.05); The fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin, and cortisol recorded in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: In the treatment of type 2 diabetes patients with depression, the choice of paroxetine can not only improve their anxiety and depression symptoms, but also ensure the effectiveness of treatment and control blood sugar within a reasonable range.

Key words: paroxetine; Depression; Type 2 diabetes; mentality; 2h postprandial blood glucose